Free tool
Oncology stocks
We cover 27 companies grouped under the Oncology theme. The median market value in the group is $347.24M. Across the group, the median move over the past trading day is 0.00%. 44% of the 25 with a 200-day average trade above it. Price change over the past year runs from −44.4% to +248.9% across the middle 80 percent of the group, with a median of −2.5%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
27 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| GXE.DE | Lakefront Biotherapeutics NV | 24.68 EUR | +0.41% | −12.36% | −44.50% |
| 0HFQ.L | AnaptysBio, Inc. | $56.87 | −3.20% | +24.44% | +183.92% |
| PHIL.MI | Philogen S.p.A. | 23.35 EUR | −2.71% | +3.88% | +2.12% |
| EUZ.DE | Eckert & Ziegler SE | 13.65 EUR | −0.29% | −9.06% | −23.06% |
| 0SZI.L | Corbus Pharmaceuticals Holdings, Inc. | $11.16 | +4.01% | +42.04% | +5.13% |
| 0QAV.L | Nanobiotix S.A. | 34.51 EUR | −2.83% | +80.19% | +346.30% |
| 0KCS.L | OPKO Health, Inc. | $1.51 | +2.03% | +16.20% | +5.63% |
| 0IL8.L | Kyntra Bio, Inc. | $7.95 | +1.50% | −11.24% | −24.41% |
| J8J.F | TransThera Sciences (Nanjing), Inc. | 1.02 EUR | −0.97% | −91.09% | −91.09% |
| ALVIO.PA | Valerio Therapeutics Société anonyme | 0.79 EUR | +5.76% | +374.47% | +1150.00% |
| 0LOV.L | Verastem, Inc. | $7.14 | +3.48% | −1.92% | −21.47% |
| AVCT.L | Avacta Group Plc | 68.80 GBP | +0.44% | +19.65% | +32.31% |
| PRTC.L | PureTech Health plc | 118.80 GBP | +0.51% | −4.65% | −11.34% |
| 0XOD.L | UroGen Pharma Ltd. | $46.35 | −1.31% | +105.18% | +136.32% |
| TNG.PA | Transgene SA | 0.81 EUR | +12.40% | −15.23% | −16.98% |
| 0IV3.L | Geron Corporation | $1.54 | 0.00% | +16.67% | +8.41% |
| IDD.DE | Innate Pharma S.A. | 1.78 EUR | +12.80% | +12.80% | −2.52% |
| IPH.PA | Innate Pharma S.A. | 1.88 EUR | +17.37% | +16.21% | +1.84% |
| BINV.ST | BioInvent International AB (publ) | 24.30 SEK | +4.07% | −17.21% | −24.30% |
| 0IMT.L | Photocure ASA | 53.80 NOK | +0.35% | −25.59% | −12.59% |
| HPHA.DE | Heidelberg Pharma AG | 2.53 EUR | −1.17% | +1.20% | −44.40% |
| SCLP.L | Scancell Holdings plc | 9.80 GBP | −1.51% | −1.01% | −6.67% |
| 0RU5.L | Oncoinvent ASA | 70.20 NOK | −18.37% | +61.75% | +5951.72% |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | 72.40 PLN | −2.95% | −3.47% | +76.16% |
| 0RDB.L | Oryzon Genomics S.A. | 2.84 EUR | +0.92% | −11.03% | +4.08% |
| RVU.WA | Ryvu Therapeutics S.A. | 18.80 PLN | +25.33% | −30.76% | −34.72% |
| FARN.L | Faron Pharmaceuticals Oy | 41.00 GBP | −4.65% | −78.97% | −80.71% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.